Pharmaxis touts progress in cystic fibrosis study
Monday, 19 December, 2005
Sydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has begun the dosing phase of its phase II clinical trial in patients with cystic fibrosis.
The study, which aims to determine the benefits of Bronchitol in children also receiving the market leading treatment, rhDNase, is being conducted at two sites in the UK.
The 42 patients enrolled in the study will receive three months treatment with each of three different therapies -- Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial will measure changes in lung function, airway inflammation, infections, and quality of life.
Full patient recruitment is expected to take about eight months
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
